First Precision Medicine Chemoprevention Trial DisappointsFirst Precision Medicine Chemoprevention Trial Disappoints

In the first precision-based chemoprevention study, erlotinib failed to significantly prevent the development of oral cancer in patients with oral premalignant lesions. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news